Kelly Maloney
Concepts (373)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 40 | 2025 | 289 | 5.730 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2025 | 79 | 1.710 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 17 | 2025 | 1742 | 1.300 |
Why?
| | Down Syndrome | 6 | 2023 | 483 | 1.290 |
Why?
| | Burkitt Lymphoma | 3 | 2024 | 63 | 0.960 |
Why?
| | Asparaginase | 8 | 2020 | 30 | 0.860 |
Why?
| | Fishes | 1 | 2024 | 111 | 0.830 |
Why?
| | Agriculture | 1 | 2024 | 99 | 0.810 |
Why?
| | Leukemia, Myeloid, Acute | 6 | 2024 | 633 | 0.770 |
Why?
| | Child | 73 | 2025 | 21936 | 0.750 |
Why?
| | Bayes Theorem | 1 | 2024 | 413 | 0.740 |
Why?
| | Consolidation Chemotherapy | 2 | 2019 | 10 | 0.670 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2025 | 1058 | 0.640 |
Why?
| | Child, Preschool | 48 | 2025 | 11158 | 0.620 |
Why?
| | Ecosystem | 1 | 2024 | 573 | 0.600 |
Why?
| | Disease-Free Survival | 12 | 2024 | 704 | 0.570 |
Why?
| | Leukemia | 4 | 2021 | 241 | 0.560 |
Why?
| | Oncogene Proteins, Fusion | 6 | 2024 | 206 | 0.550 |
Why?
| | Mercaptopurine | 5 | 2017 | 15 | 0.520 |
Why?
| | Prognosis | 16 | 2025 | 3995 | 0.500 |
Why?
| | Recurrence | 12 | 2025 | 1085 | 0.470 |
Why?
| | Antineoplastic Agents | 7 | 2019 | 2152 | 0.470 |
Why?
| | Preleukemia | 1 | 2015 | 2 | 0.460 |
Why?
| | Infant | 35 | 2025 | 9577 | 0.460 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2016 | 125 | 0.450 |
Why?
| | Molecular Targeted Therapy | 3 | 2021 | 413 | 0.440 |
Why?
| | Drug Hypersensitivity | 3 | 2017 | 95 | 0.440 |
Why?
| | Leukemia, Monocytic, Acute | 1 | 2014 | 3 | 0.440 |
Why?
| | Sarcoma, Myeloid | 1 | 2014 | 4 | 0.430 |
Why?
| | Neoplasm, Residual | 7 | 2023 | 131 | 0.410 |
Why?
| | Adolescent | 41 | 2025 | 21581 | 0.400 |
Why?
| | Bone Marrow Transplantation | 1 | 2014 | 292 | 0.390 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 26 | 0.380 |
Why?
| | Medical Oncology | 5 | 2025 | 304 | 0.370 |
Why?
| | Erwinia | 2 | 2020 | 3 | 0.370 |
Why?
| | Tumor Suppressor Proteins | 3 | 1999 | 322 | 0.360 |
Why?
| | Humans | 85 | 2025 | 138972 | 0.360 |
Why?
| | Acute Kidney Injury | 1 | 2019 | 812 | 0.360 |
Why?
| | Chromosome Aberrations | 2 | 2022 | 159 | 0.350 |
Why?
| | Neutropenia | 2 | 2022 | 157 | 0.340 |
Why?
| | Male | 57 | 2025 | 68250 | 0.340 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2019 | 661 | 0.340 |
Why?
| | Stem Cell Transplantation | 3 | 2019 | 184 | 0.330 |
Why?
| | Rhabdomyosarcoma | 1 | 2011 | 74 | 0.320 |
Why?
| | Cell Cycle Proteins | 3 | 1999 | 617 | 0.320 |
Why?
| | Carrier Proteins | 3 | 1999 | 737 | 0.320 |
Why?
| | Sarcoma, Ewing | 1 | 2011 | 100 | 0.310 |
Why?
| | Ploidies | 2 | 2019 | 17 | 0.310 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 184 | 0.300 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 3 | 2021 | 29 | 0.290 |
Why?
| | Survival Rate | 8 | 2024 | 1934 | 0.290 |
Why?
| | Genes, Tumor Suppressor | 2 | 1999 | 81 | 0.290 |
Why?
| | Catheter-Related Infections | 2 | 2022 | 89 | 0.290 |
Why?
| | Cyclophosphamide | 4 | 2019 | 255 | 0.290 |
Why?
| | Female | 55 | 2025 | 74016 | 0.280 |
Why?
| | Catheterization, Central Venous | 2 | 2022 | 113 | 0.280 |
Why?
| | Philadelphia Chromosome | 2 | 2018 | 18 | 0.270 |
Why?
| | Medication Adherence | 3 | 2017 | 505 | 0.260 |
Why?
| | Gene Deletion | 2 | 1998 | 389 | 0.250 |
Why?
| | Vincristine | 4 | 2021 | 129 | 0.240 |
Why?
| | Trisomy | 2 | 2021 | 74 | 0.240 |
Why?
| | Neoplasm Proteins | 2 | 2018 | 433 | 0.240 |
Why?
| | Antimetabolites, Antineoplastic | 2 | 2017 | 93 | 0.240 |
Why?
| | Etoposide | 2 | 2019 | 162 | 0.240 |
Why?
| | Ikaros Transcription Factor | 1 | 2025 | 24 | 0.230 |
Why?
| | Young Adult | 15 | 2024 | 13371 | 0.220 |
Why?
| | Maryland | 1 | 2024 | 61 | 0.220 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 3 | 1999 | 68 | 0.220 |
Why?
| | Invertebrates | 1 | 2024 | 25 | 0.210 |
Why?
| | Treatment Outcome | 12 | 2023 | 10921 | 0.210 |
Why?
| | Rivers | 1 | 2024 | 64 | 0.210 |
Why?
| | PAX5 Transcription Factor | 2 | 2024 | 14 | 0.210 |
Why?
| | Anxiety | 3 | 2016 | 1070 | 0.210 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2025 | 2138 | 0.200 |
Why?
| | Genomics | 4 | 2025 | 797 | 0.200 |
Why?
| | Gene Rearrangement | 3 | 2019 | 151 | 0.190 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 76 | 0.190 |
Why?
| | Leukemia, Myelomonocytic, Juvenile | 1 | 2022 | 4 | 0.190 |
Why?
| | Polyethylene Glycols | 5 | 2020 | 631 | 0.190 |
Why?
| | Health Equity | 1 | 2024 | 99 | 0.190 |
Why?
| | Induction Chemotherapy | 2 | 2019 | 78 | 0.180 |
Why?
| | Central Venous Catheters | 1 | 2022 | 51 | 0.180 |
Why?
| | Environmental Monitoring | 1 | 2024 | 365 | 0.180 |
Why?
| | Doxorubicin | 2 | 2022 | 350 | 0.180 |
Why?
| | Program Evaluation | 2 | 2017 | 917 | 0.170 |
Why?
| | Prednisone | 2 | 2019 | 226 | 0.170 |
Why?
| | Lymphoma | 1 | 2023 | 229 | 0.170 |
Why?
| | Adult | 23 | 2023 | 38393 | 0.170 |
Why?
| | Biomarkers, Tumor | 2 | 2025 | 1229 | 0.170 |
Why?
| | Lung Neoplasms | 1 | 2014 | 2533 | 0.170 |
Why?
| | Translocation, Genetic | 2 | 2013 | 109 | 0.160 |
Why?
| | Maintenance Chemotherapy | 2 | 2017 | 36 | 0.160 |
Why?
| | Bacterial Infections | 1 | 2022 | 245 | 0.160 |
Why?
| | Immunocompromised Host | 1 | 2021 | 201 | 0.160 |
Why?
| | Diploidy | 1 | 2019 | 16 | 0.160 |
Why?
| | Risk Factors | 11 | 2022 | 10385 | 0.160 |
Why?
| | Genes, p16 | 1 | 1999 | 15 | 0.150 |
Why?
| | Quality of Life | 3 | 2024 | 2962 | 0.150 |
Why?
| | Hyperglycemia | 1 | 2023 | 357 | 0.150 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 1998 | 24 | 0.150 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1998 | 55 | 0.150 |
Why?
| | Myelodysplastic Syndromes | 1 | 2020 | 141 | 0.150 |
Why?
| | Antibodies, Bispecific | 1 | 2019 | 55 | 0.150 |
Why?
| | Prospective Studies | 9 | 2022 | 7661 | 0.140 |
Why?
| | Rituximab | 1 | 2019 | 202 | 0.140 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 1998 | 71 | 0.140 |
Why?
| | Mutagenesis | 1 | 1999 | 183 | 0.140 |
Why?
| | Prostate-Specific Antigen | 2 | 2009 | 165 | 0.140 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2020 | 184 | 0.140 |
Why?
| | Proto-Oncogenes | 1 | 1997 | 28 | 0.130 |
Why?
| | Patient Safety | 1 | 2021 | 332 | 0.130 |
Why?
| | Family Relations | 2 | 2016 | 92 | 0.130 |
Why?
| | Thioguanine | 1 | 2017 | 19 | 0.130 |
Why?
| | Thionucleotides | 1 | 2017 | 35 | 0.130 |
Why?
| | Apyrase | 1 | 2017 | 24 | 0.130 |
Why?
| | Oncologists | 1 | 2017 | 43 | 0.130 |
Why?
| | Follow-Up Studies | 6 | 2021 | 5152 | 0.130 |
Why?
| | Blast Crisis | 1 | 2016 | 33 | 0.130 |
Why?
| | Carboxypeptidases A | 1 | 2016 | 2 | 0.130 |
Why?
| | Pediatricians | 1 | 2017 | 129 | 0.120 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 276 | 0.120 |
Why?
| | Retrospective Studies | 10 | 2023 | 15901 | 0.120 |
Why?
| | Sepsis | 1 | 2022 | 611 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 496 | 0.120 |
Why?
| | Osteonecrosis | 1 | 2015 | 24 | 0.120 |
Why?
| | Nausea | 1 | 2016 | 111 | 0.120 |
Why?
| | Depression | 2 | 2016 | 1470 | 0.120 |
Why?
| | Mentors | 2 | 2017 | 209 | 0.120 |
Why?
| | Pancreatitis | 1 | 2016 | 133 | 0.110 |
Why?
| | Central Nervous System Neoplasms | 1 | 2017 | 165 | 0.110 |
Why?
| | Longitudinal Studies | 7 | 2016 | 2850 | 0.110 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 280 | 0.110 |
Why?
| | Mentoring | 1 | 2017 | 150 | 0.110 |
Why?
| | Dexamethasone | 4 | 2021 | 375 | 0.110 |
Why?
| | Mutation | 4 | 2022 | 3984 | 0.110 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2016 | 70 | 0.110 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 3 | 1999 | 16 | 0.110 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 2 | 2010 | 70 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 543 | 0.110 |
Why?
| | Bacteremia | 1 | 2016 | 214 | 0.110 |
Why?
| | Antigens, CD | 1 | 2017 | 537 | 0.110 |
Why?
| | Cross Infection | 1 | 2016 | 249 | 0.100 |
Why?
| | Repressor Proteins | 1 | 1997 | 423 | 0.100 |
Why?
| | Flow Cytometry | 1 | 2018 | 1192 | 0.100 |
Why?
| | Pediatrics | 3 | 2021 | 1079 | 0.100 |
Why?
| | Life Change Events | 1 | 2014 | 153 | 0.100 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2013 | 42 | 0.100 |
Why?
| | DNA-Binding Proteins | 2 | 1998 | 1473 | 0.100 |
Why?
| | Histone-Lysine N-Methyltransferase | 2 | 2010 | 134 | 0.100 |
Why?
| | Immunotherapy | 1 | 2018 | 633 | 0.100 |
Why?
| | Leukemia, Megakaryoblastic, Acute | 1 | 2012 | 10 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 324 | 0.100 |
Why?
| | Transcription Factors | 2 | 1998 | 1701 | 0.100 |
Why?
| | Quality Improvement | 1 | 2021 | 1215 | 0.100 |
Why?
| | Myeloproliferative Disorders | 1 | 2012 | 27 | 0.090 |
Why?
| | Self Report | 1 | 2017 | 842 | 0.090 |
Why?
| | Karyotyping | 3 | 2019 | 103 | 0.090 |
Why?
| | Contraindications | 1 | 2012 | 86 | 0.090 |
Why?
| | Arabinonucleosides | 1 | 2011 | 8 | 0.090 |
Why?
| | Adenine Nucleotides | 1 | 2011 | 24 | 0.090 |
Why?
| | Cohort Studies | 5 | 2021 | 5744 | 0.090 |
Why?
| | Prostatic Neoplasms | 2 | 2009 | 1046 | 0.090 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 1437 | 0.090 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2010 | 19 | 0.080 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2010 | 32 | 0.080 |
Why?
| | Pain | 1 | 2016 | 779 | 0.080 |
Why?
| | Multivariate Analysis | 4 | 2015 | 1497 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1985 | 0.080 |
Why?
| | Age Factors | 8 | 2019 | 3276 | 0.070 |
Why?
| | Parents | 2 | 2016 | 1423 | 0.070 |
Why?
| | Prostatectomy | 1 | 2009 | 102 | 0.070 |
Why?
| | Bloom Syndrome | 1 | 1988 | 3 | 0.070 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 667 | 0.070 |
Why?
| | Juxtaglomerular Apparatus | 1 | 2007 | 2 | 0.070 |
Why?
| | Gene Expression Regulation, Leukemic | 2 | 2016 | 55 | 0.070 |
Why?
| | Risk Assessment | 4 | 2024 | 3466 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 1047 | 0.070 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 769 | 0.060 |
Why?
| | Blood Coagulation | 1 | 2008 | 262 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2024 | 1034 | 0.060 |
Why?
| | Stress, Psychological | 1 | 2014 | 1124 | 0.060 |
Why?
| | Animals | 3 | 2024 | 37243 | 0.060 |
Why?
| | Surveys and Questionnaires | 4 | 2024 | 5884 | 0.060 |
Why?
| | Methotrexate | 2 | 2017 | 255 | 0.060 |
Why?
| | Remission Induction | 2 | 2019 | 292 | 0.060 |
Why?
| | Drug Monitoring | 2 | 2017 | 209 | 0.060 |
Why?
| | Case-Control Studies | 3 | 2024 | 3574 | 0.050 |
Why?
| | Acute Disease | 2 | 2019 | 993 | 0.050 |
Why?
| | Selection Bias | 1 | 2024 | 39 | 0.050 |
Why?
| | Personal Satisfaction | 2 | 2017 | 214 | 0.050 |
Why?
| | Administration, Oral | 2 | 2017 | 787 | 0.050 |
Why?
| | Incidence | 3 | 2019 | 2830 | 0.050 |
Why?
| | Genetic Variation | 1 | 1988 | 990 | 0.050 |
Why?
| | Kidney Neoplasms | 1 | 2007 | 395 | 0.050 |
Why?
| | Risk | 5 | 2023 | 913 | 0.050 |
Why?
| | Disease Progression | 2 | 2021 | 2752 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2022 | 12 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2020 | 1522 | 0.050 |
Why?
| | Transcriptome | 2 | 2019 | 966 | 0.040 |
Why?
| | Exome | 1 | 2022 | 237 | 0.040 |
Why?
| | Drug Therapy | 1 | 2021 | 85 | 0.040 |
Why?
| | Menorrhagia | 1 | 2001 | 22 | 0.040 |
Why?
| | Diarrhea | 2 | 1999 | 182 | 0.040 |
Why?
| | Bone Marrow | 1 | 2022 | 299 | 0.040 |
Why?
| | Endocrine Glands | 1 | 1979 | 16 | 0.040 |
Why?
| | Blood Cell Count | 1 | 1999 | 54 | 0.040 |
Why?
| | Chromosomes, Human | 1 | 2019 | 44 | 0.040 |
Why?
| | Azacitidine | 1 | 2020 | 139 | 0.040 |
Why?
| | Viral Load | 1 | 2021 | 495 | 0.040 |
Why?
| | Genome-Wide Association Study | 2 | 2016 | 1391 | 0.040 |
Why?
| | Cytogenetic Analysis | 1 | 2019 | 34 | 0.040 |
Why?
| | Loss of Heterozygosity | 1 | 1999 | 51 | 0.040 |
Why?
| | Mosaicism | 1 | 2019 | 74 | 0.040 |
Why?
| | Disinfectants | 1 | 1999 | 41 | 0.040 |
Why?
| | Sequence Deletion | 1 | 1999 | 184 | 0.040 |
Why?
| | Hypertension | 1 | 2007 | 1249 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2020 | 227 | 0.040 |
Why?
| | Chromosomes | 1 | 2019 | 105 | 0.040 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2018 | 48 | 0.040 |
Why?
| | Infant, Newborn | 4 | 2019 | 6158 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2021 | 805 | 0.040 |
Why?
| | Escherichia coli O157 | 1 | 1998 | 34 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 573 | 0.040 |
Why?
| | Methylation | 1 | 1998 | 227 | 0.030 |
Why?
| | United States | 4 | 2021 | 15074 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 2 | 2017 | 2362 | 0.030 |
Why?
| | Biopsy | 1 | 2021 | 1072 | 0.030 |
Why?
| | Community Participation | 1 | 1999 | 133 | 0.030 |
Why?
| | Erythrocyte Count | 1 | 2017 | 21 | 0.030 |
Why?
| | Glucose | 1 | 2023 | 1031 | 0.030 |
Why?
| | Escherichia coli Infections | 1 | 1998 | 115 | 0.030 |
Why?
| | Food-Drug Interactions | 1 | 2017 | 11 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2017 | 82 | 0.030 |
Why?
| | Injections, Intramuscular | 1 | 2017 | 131 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 1997 | 56 | 0.030 |
Why?
| | Leucovorin | 1 | 2017 | 85 | 0.030 |
Why?
| | Career Mobility | 1 | 2017 | 70 | 0.030 |
Why?
| | Family | 1 | 2021 | 680 | 0.030 |
Why?
| | Dairy Products | 1 | 2017 | 35 | 0.030 |
Why?
| | Water Purification | 1 | 1999 | 151 | 0.030 |
Why?
| | Cerebrospinal Fluid | 1 | 2017 | 91 | 0.030 |
Why?
| | MEF2 Transcription Factors | 1 | 2016 | 59 | 0.030 |
Why?
| | Cranial Irradiation | 1 | 2017 | 85 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2021 | 980 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 411 | 0.030 |
Why?
| | Sulfonamides | 1 | 2020 | 505 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2017 | 325 | 0.030 |
Why?
| | Luciferases | 1 | 2016 | 150 | 0.030 |
Why?
| | NIH 3T3 Cells | 1 | 2016 | 148 | 0.030 |
Why?
| | Methyltransferases | 1 | 2017 | 72 | 0.030 |
Why?
| | Hemorrhage | 1 | 2001 | 747 | 0.030 |
Why?
| | Methyl Ethers | 1 | 1996 | 15 | 0.030 |
Why?
| | Ethers | 1 | 1996 | 19 | 0.030 |
Why?
| | Bone Morphogenetic Protein 7 | 1 | 2015 | 12 | 0.030 |
Why?
| | Fluorides | 1 | 1996 | 49 | 0.030 |
Why?
| | Cytarabine | 1 | 2016 | 63 | 0.030 |
Why?
| | Breast Neoplasms | 5 | 1979 | 2283 | 0.030 |
Why?
| | Genotype | 3 | 2017 | 1849 | 0.030 |
Why?
| | Anesthetics, Inhalation | 1 | 1996 | 48 | 0.030 |
Why?
| | Health Education | 1 | 1999 | 360 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2017 | 2849 | 0.030 |
Why?
| | Middle Aged | 10 | 2019 | 33782 | 0.030 |
Why?
| | Spinal Dysraphism | 1 | 1996 | 95 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2017 | 227 | 0.030 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2016 | 209 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 621 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 1998 | 509 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 1999 | 1235 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 731 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2016 | 262 | 0.030 |
Why?
| | Qualitative Research | 1 | 2021 | 1448 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 449 | 0.030 |
Why?
| | DNA Methylation | 1 | 1999 | 636 | 0.030 |
Why?
| | Behavior | 1 | 2014 | 92 | 0.030 |
Why?
| | Algorithms | 1 | 2021 | 1730 | 0.030 |
Why?
| | Psychomotor Agitation | 1 | 2014 | 73 | 0.030 |
Why?
| | Demography | 1 | 2014 | 298 | 0.030 |
Why?
| | Aged | 9 | 2019 | 24172 | 0.030 |
Why?
| | Marriage | 1 | 2014 | 122 | 0.030 |
Why?
| | Income | 1 | 2014 | 207 | 0.030 |
Why?
| | Base Sequence | 1 | 2016 | 2176 | 0.020 |
Why?
| | Blood Glucose | 1 | 2023 | 2241 | 0.020 |
Why?
| | Prevalence | 2 | 2016 | 2745 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2013 | 310 | 0.020 |
Why?
| | Odds Ratio | 1 | 2015 | 1084 | 0.020 |
Why?
| | Nucleoside Transport Proteins | 1 | 2011 | 8 | 0.020 |
Why?
| | Aggression | 1 | 2014 | 200 | 0.020 |
Why?
| | Kidney | 2 | 1996 | 1467 | 0.020 |
Why?
| | Time Factors | 2 | 2015 | 6869 | 0.020 |
Why?
| | Regression Analysis | 1 | 2014 | 1021 | 0.020 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2011 | 70 | 0.020 |
Why?
| | Erythrocytes | 1 | 2017 | 701 | 0.020 |
Why?
| | Escherichia coli | 1 | 2015 | 827 | 0.020 |
Why?
| | Mice | 2 | 2019 | 17828 | 0.020 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2011 | 191 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 1311 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 2093 | 0.020 |
Why?
| | Bacteria | 1 | 2016 | 868 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 2994 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 897 | 0.020 |
Why?
| | Sister Chromatid Exchange | 1 | 1988 | 4 | 0.020 |
Why?
| | Genetic Complementation Test | 1 | 1988 | 66 | 0.020 |
Why?
| | Cell Fusion | 1 | 1988 | 50 | 0.020 |
Why?
| | Emotions | 1 | 2014 | 568 | 0.020 |
Why?
| | Water Microbiology | 2 | 1999 | 85 | 0.020 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2008 | 86 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 5801 | 0.020 |
Why?
| | Protein C | 1 | 2008 | 53 | 0.020 |
Why?
| | Antithrombins | 1 | 2008 | 62 | 0.020 |
Why?
| | Genetic Markers | 1 | 1988 | 344 | 0.020 |
Why?
| | Fibrinogen | 1 | 2008 | 173 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2008 | 406 | 0.020 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 76 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2007 | 187 | 0.020 |
Why?
| | Rare Diseases | 1 | 2007 | 108 | 0.020 |
Why?
| | Blood Pressure Determination | 1 | 2007 | 143 | 0.020 |
Why?
| | Nephrectomy | 1 | 2007 | 155 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4095 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2011 | 2815 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1730 | 0.010 |
Why?
| | Cell Line | 1 | 1988 | 2879 | 0.010 |
Why?
| | Anemia, Hypochromic | 1 | 2001 | 3 | 0.010 |
Why?
| | Blood Platelet Disorders | 1 | 2001 | 10 | 0.010 |
Why?
| | von Willebrand Diseases | 1 | 2001 | 28 | 0.010 |
Why?
| | Estriol | 1 | 1979 | 6 | 0.010 |
Why?
| | Estrone | 1 | 1979 | 36 | 0.010 |
Why?
| | Menstruation | 1 | 1979 | 43 | 0.010 |
Why?
| | Prolactin | 1 | 1979 | 95 | 0.010 |
Why?
| | Thrombocytopenia | 1 | 2001 | 205 | 0.010 |
Why?
| | Bolivia | 1 | 1999 | 56 | 0.010 |
Why?
| | Luteinizing Hormone | 1 | 1979 | 183 | 0.010 |
Why?
| | Follicle Stimulating Hormone | 1 | 1979 | 243 | 0.010 |
Why?
| | Restaurants | 1 | 1998 | 25 | 0.010 |
Why?
| | Food Handling | 1 | 1998 | 66 | 0.010 |
Why?
| | Swimming | 1 | 1998 | 50 | 0.010 |
Why?
| | Progesterone | 1 | 1979 | 258 | 0.010 |
Why?
| | Disease Transmission, Infectious | 1 | 1998 | 68 | 0.010 |
Why?
| | Water Supply | 1 | 1998 | 77 | 0.010 |
Why?
| | Meat | 1 | 1998 | 97 | 0.010 |
Why?
| | Kyphosis | 1 | 1996 | 37 | 0.010 |
Why?
| | Halothane | 1 | 1996 | 7 | 0.010 |
Why?
| | Estradiol | 1 | 1979 | 525 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1999 | 1317 | 0.010 |
Why?
| | Congenital Abnormalities | 1 | 1996 | 93 | 0.010 |
Why?
| | Population Surveillance | 1 | 1999 | 482 | 0.010 |
Why?
| | Feces | 1 | 1998 | 481 | 0.010 |
Why?
| | Diagnostic Imaging | 1 | 1996 | 320 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 1978 | 573 | 0.010 |
Why?
| | Pedigree | 3 | 1978 | 510 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 1999 | 7685 | 0.000 |
Why?
| | Nebraska | 2 | 1976 | 19 | 0.000 |
Why?
| | New York | 2 | 1976 | 126 | 0.000 |
Why?
| | Genes | 1 | 1978 | 227 | 0.000 |
Why?
| | Genetic Linkage | 1 | 1978 | 289 | 0.000 |
Why?
| | Oncogenic Viruses | 1 | 1976 | 3 | 0.000 |
Why?
| | Apocrine Glands | 1 | 1976 | 4 | 0.000 |
Why?
| | Genetic Techniques | 1 | 1976 | 67 | 0.000 |
Why?
| | Pheochromocytoma | 1 | 1976 | 57 | 0.000 |
Why?
| | Syndrome | 1 | 1976 | 377 | 0.000 |
Why?
| | Statistics as Topic | 1 | 1976 | 299 | 0.000 |
Why?
| | Klinefelter Syndrome | 1 | 1976 | 67 | 0.000 |
Why?
| | HLA Antigens | 1 | 1976 | 233 | 0.000 |
Why?
| | Skin Diseases | 1 | 1976 | 145 | 0.000 |
Why?
| | Pregnancy | 2 | 1978 | 6870 | 0.000 |
Why?
| | Abnormalities, Multiple | 1 | 1976 | 195 | 0.000 |
Why?
| | Sarcoma | 1 | 1976 | 189 | 0.000 |
Why?
| | Sex Factors | 1 | 1978 | 2050 | 0.000 |
Why?
| | Thyroid Neoplasms | 1 | 1976 | 324 | 0.000 |
Why?
| | Neoplasms | 2 | 1976 | 2687 | 0.000 |
Why?
| | Melanoma | 1 | 1976 | 757 | 0.000 |
Why?
| | Registries | 1 | 1976 | 2081 | 0.000 |
Why?
| | Phenotype | 1 | 1976 | 3143 | 0.000 |
Why?
| | Brain Neoplasms | 1 | 1976 | 1267 | 0.000 |
Why?
|
|
Maloney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|